Статья
ПРОБЛЕМА ЛЕКАРСТВЕННОГО ВЗАИМОДЕЙСТВИЯ В КАРДИОЛОГИЧЕСКОЙ ПРАКТИКЕ: ЧТО ДОЛЖЕН УЧИТЫВАТЬ ВРАЧ?
В статье представлен обзор данных, доступных отечественных и зарубежных источников, в отношении лекарственного взаимодействия и выбора лекарственных препаратов с учетом этих данных. Представлены данные, касающиеся статинов, антагонистов рецепторов ангиотензина II, ацетилсалициловой кислоты и антагонистов ренин-ангиотензин-альдостероновой системы. Основным итогом представленного обзора литературы является заключение о том, что врачи в своей практической деятельности должны учитывать возможность лекарственного взаимодействия и обращать внимание на этот раздел в инструкции лекарственных препаратов и на соответствующих электронных ресурсах, адреса которых представлены в статье.
1. Doan J, Zakrzewski-Jakubiak H, Roy J, et al. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013 Mar; 47(3):324-32.
2. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011 May;71(5):684-700.
3. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004; 329(7456):15-9.
4. Wu D, Mansoor G, Kempf Ch. Clinical attributes, treatment, and control in hypertension (CATCH)—a French and Italian longitudinal patient database study. Clinical Hypertension 2015;21:18.
5. Carter BL, Lund BC, Hayase N, et al. The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens 2002;15(11):953-7.
6. Clinical pharmacology: textbook for universities. Ed. Kukes VG. GEOTAR-Media; 2009. Russian (Клиническая фармакология. Учебник для вузов. Под ред. В.Г. Кукеса. 4-е издание. ГЭОТАР-Медиа; 2009).
7. Tashenova AI. Transport system of P glycoprotein and pharmacokinetics of drugs. Biomedicine 2010; 4: 24-32. Russian (Ташенова А.И. Транспортная система гликопротеина Р и фармакокинетика лекарственных средств. Биомедицина 2010, 4:24-32).
8. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94:1140-6.
9. Williams D, Feely J. Pharmacokinetic pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 4:343-70.
10. FDA Centers for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for industry. Drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. February 2012. http://www.fda.gov/downloads/Drugs/Guidance Comp liance Regulatory Information/Guidances/UCM292362 .pdf . (Accessed March 15, 2012).
11. Kobalava JD. Clinical aspects of drug interactions in cardiology. Practical angiology. Online resource. 01.10.2015. Russian (Кобалава Ж.Д. Клинические аспекты проблемы лекарственных взаимодействий в кардиологии. Практическая ангиология. Интернет ресурс. 01.10.2015) http://www.healthua.org/issues/angio/1.html .
12. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductaseinhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006 Oct;112(1):71-105
13. Concurrent Macrolide Antibiotic May Increase Statin Toxicity. Ann Intern Med. https://medicoblog.wordpress.com/2013/06/23/concurrent-macrolide-antibiotic-mayincrease-statin-toxicity/ Дата обращения: 10.10.2015.
14. IMPORTANT NEW PRESCRIBING ADVICE FOR ATORVASTATIN (Lipitor), 3 December 2007, Medical Information Pfizer Limited Walton Oaks Dorking Road Tadworth Surrey KT207NS United Kingdom
15. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMGCoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013 Oct;52(10):815-31.
16. Neuvonen PJ. Drug interactions with HMG-CoA reductaseinhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010 Mar;11(3):323-32.
17. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81.
18. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%9A%D1%80%D0%B5%D1%81%D1%82%D0%BE%D1%80&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=&order=RegDate&orderType=desc&pageNum=1
19. Calza L, Manfredi R, Colangeli V. Efficacy and safety of atazanavir-ritonavir plus abacavirlamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS. 2009 Sep;23(9):691-7.
20. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%9B%D0%B8%D0%BF%D1%80%D0%B8%D0%BC%D0%B0%D1%80&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=&order=RegDate&orderType=desc&pageNum=1.
21. Franco D, Henao Y, Monsalve M, et al. Interactions of lipid lowering agents: an approach to establish and assess its clinical relevance. Farm Hosp. 2013; 37 (6): 539-57.
22. Gotto AM, Toth PP. Сomprehensive management of high risk cardiovascular patients. Pl detail-document #280405. Pharmacist’s letter -Prescriber’s letter. http://medical.dentalebooks.com/31682/comprehensive-management-of-high-risk-cardiovascularpatients.html. Дата обращения10.10.2015.
23. Holtzman CW, Wiggins BS, Spinler SA. Role of pglycoprotein in statin drug interactions. Pharmacotherapy 2006; 26:1601-7.
24. Bacic-Vrca V, Marusic S, Erdeljic V, et al. The incidence of potential drug–drug interactions in elderly patients with arterial hypertension. Pharm World Sci 32(6): 815-21.
25. Villa J, Cano A, Franco D, et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Aten Primaria 2014; 46(9):464-74.
26. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013 Jan 8; 346:e8525.
27. Drug Interactions Checker. http://www.drugs.com/drug_interactions.php. Дата обращения 10.10.2015.
28. MacIntrye IM, Jhund PS, McMurray JJ. Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. Cardiovasc Drugs Ther 2005;19(4):261-5.
29. Syvolap VV, Kolesnik YM. Antiplatelet therapy and chronic heart failure. Internal medicine 2007;6(6). Russian (В.В. Сыволап, М.Ю. Колесник. Антитромбоцитарная терапия и хроническая сердечная недостаточность. Внутренняя медицина 2007; 6(6)).
30. Nguyen KhN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the cooperative new Scandinavian enalapril Survival study II (CONSENSUS II). Am J Cardiol 1997;79:115-9.
31. Bosch J, Lonn E, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.HOPE/HOPE-TOO Study Investigators. Circulation 2005; 112(9):1339-46.
32. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1999;5.
33. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
34. The EPILOG Investigators. Platelet glycoprotein IIb-IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997;336: 1689-96.
35. Peterson JG, Topol EJ, Sapp SK, et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000;109: 371-7.
36. Lindenfeld J, Robertson AD, Lowes BD, et al. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. MOCHA (Multicenter Oral Carvedilol Heart failure Assessment) Investigators. J Am Coll Cardiol. 2001;12(7) :1950-6.
37. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and assence of aspirin. J Am Coll Cardiol 2000;35:1801-7.
38. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
39. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensinconverting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-42.
40. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics trial. Journal of Cardiac Failure 2004;10: 101-2.
41. Kozdağ G, Yaymacı M, Ertaş G, et al. Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. Heart Vessels 2012;27(6):568-75.
42. Guazzi M, Brambilla R, Reina G, et al. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Аrch Intern Med 2003; 163(13):1574-9.
43. Borghi C, Ambrosioni E, Novo S, et al. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35 (7):416-23.
44. Chang SM, Granger CB, Johansson PA, et al. CHARM Investigators. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2010 Jul;12(7):738-45
45. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%90
46. %D1%81%D0%BF%D0%B8%D1%80%D0%B8%D0%BD+%D0%BA%D0%B0%D1%80%D0%B4%D0%B8%D0%BE&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=1®type=&order=RegDate&orderType=desc&pageNum=1
47. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%9F%D0%BB%D0%B0%D0%B2%D0%B8%D0%BA%D1%81&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=1®type=&order=RegDate&orderType=desc&pageNum=1
48. National guidelines PRAS, CSC and REMOT for the diagnosis and treatment of chronic heart failure (fourth revision). Heart failure 2013; 7:81-94. Russian (Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность 2013; 7:81-94).
49. Tarlovskaya EI. Generic medicines in real clinical practice. Hypertension 2009;4(15): 512-515. Russian. (Тарловская Е.И. Генерики в реальной клинической практике. Артериальная гипертония 2009;4(15): 512-5).
50. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%92%D0%B0%D0%BB%D0%B7&OwnerName=&MnfOrg=&MnfOrgCountr=&isfs=0&isND=-1®type=&order=RegDate&orderType=desc&pageNum=1
51. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%A0%D0%BE%D0%B7%D0%B0%D1%80%D1%82&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=1®type=&order=RegDate&orderType=desc&pageNum=1
52. http://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=&lf=&TradeNmR=%D0%9B%D0%BE%D0%BF%D0%B8%D1%80%D0%B5%D0%BB&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=1®type=&order=RegDate&orderType=desc&pageNum=1
53. Tarlovskaya EI, Nechaeva GI, Malchikova SV, et al. Forecasting of the influence of original and generic rosuvastatina on direct medical costs in secondary prevention in patients with chronic forms of coronary artery disease. Cardiovascular Therapy and Prevention 2015;4: 29-38. Russian (Тарловская Е.И. Нечаева Г.И., Мальчикова С.В., Семенкин А.А. Прогнозирование влияния оригинального и генерического розувастатина на прямые медицинские затраты при вторичной профилактике у пациентов с хроническими формами ИБС. Кардиоваскулярная терапия и профилактика 2015;4: 29-38).
54. Lozovskaya A. Antiplatelet therapy: present and future. Effective pharmacotherapy, cardiology and angiology 2011; 3. Russian (Лозовская А. Антиагрегантная терапия: настоящее и будущее. Эффективная фармакотерапия, кардиология и ангиология 2011; 3).
55. Martsevich SYu, Lukin VYu, Dmitrieva NA, et al. Comparative study of the efficacy and tolerability of generic and original drugs valsartan in monotherapy or in combination with hydrochlorothiazide and bisoprolol in patients with arterial hypertension of 1-2 degrees and metabolic syndrome. Rational pharmacotherapy in cardiology, 2012; 8(1): 17-22. Russian (Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и соавт. Сравнительное изучение эффективности и переносимости дженерического и оригинального препаратов валсартана в виде монотерапии или в комбинации с гидрохлоротиазидом и бисопрололом у больных артериальной гипертонией 1-2 степени и метаболическим синдромом. Рациональная фармакотерапия в кардиологии, 2012; 8(1): 17-22).